A study showed that intranasal delivery with a NEO100-based formulation enables noninvasive, therapeutic delivery to the brain of a pharmaceutical agent that otherwise does not efficiently cross the BBB. One such agent is bortezomib (BZM), a proteasome inhibitor that is approved for the treatment of multiple myeloma. Preclinical studies established that BZM can be effective […]
Many pharmaceutical agents are highly potent but are unable to exert therapeutic activity against disorders of the central nervous system {CNS) because the blood-brain barrier (BBB) impedes their brain entry. Preclinical studies established that Bortezomib (BZM), a proteasome inhibitor that is approved for the treatment of multiple myeloma, can be effective against glioblastoma {GBM), but […]
Glioblastoma (GBM) is a highly aggressive primary brain tumor with a poor prognosis. Treatment with temozolomide, the current standard of care for gliomas, usually results in drug resistance and tumor recurrence. Therefore, there is a great need for drugs that target GBM. In response to this, NeOnc Technologies Holdings, Inc. created NEO214 by covalently linking […]
